TScan Therapeutics Inc.

TScan Therapeutics Inc. annual/quarterly operating income history and growth rate from 2020 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.

• TScan Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -29.1 M, a 19.62% decrease year-over-year.
• TScan Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -141.1 M, a 14.84% increase year-over-year.
• TScan Therapeutics Inc. annual operating income for 2025 was -135.8 M, a 0.74% increase from 2024.
• TScan Therapeutics Inc. annual operating income for 2024 was -134.8 M, a 44.26% increase from 2023.
• TScan Therapeutics Inc. annual operating income for 2023 was -93.5 M, a 40.25% increase from 2022.
• TScan Therapeutics Inc. annual operating income for 2022 was -66.6 M.